Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XMT 1592

Next Previous
Search
Drug Profile

XMT 1592

Alternative Names: XMT-1592

Latest Information Update: 19 Oct 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Recepta biopharma
  • Developer Mersana Therapeutics
  • Class Antibodies; Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 06 Oct 2023 Mersana Therapeutics terminates a phase Ib trial in Non-small cell lung cancer, Ovarian cancer, Fallopian tube cancer, Peritoneal cancer in USA (IV, Infusion) due to discontinuation of the development programme (NCT04396340)
  • 31 Jan 2021 Mersana Therapeutics has patents pending for XMT 1592 and Dolasynthen platform in USA and other countries (Mersana Therapeutics FORM 10-K, February 2021)
  • 22 Jun 2020 Pharmacokinetics and pharmacodynamics data from preclinical studies in Ovarian cancer and Non-small cell lung cancer presented at the 111th Annual Meeting of the American Association for Cancer Research - II (AACR-II-2020)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top